site stats

Hochmair et al. j thorac oncol. 2017 12:s2137

NettetStudy Oversight This study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International … Nettet23. mar. 2024 · Baseline characteristics of the 129 patients with NSCLC treated with nivolumab have been described previously. 11 Median age was 65 years, 61.2% of the patients were male, 19.4% had received only a single line of prior systemic therapy, and 57.4% had nonsquamous tumor histology.

Pemetrexed plus platinum with or without pembrolizumab in

NettetJournal of Thoracic Oncology Vol 12, Issue 12, Pages A1-A20, e193-e210, 1737-1860 (December 2024) ScienceDirect.com by Elsevier ADVERTISEMENT Journal of … NettetWang J. et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 2024; 25: 4663-4673. ... J Thorac … the future tarot https://prismmpi.com

EGFR - ScienceDirect

Nettet1. sep. 2024 · The EGFR T790M gatekeeper mutation in exon 20 develops in 50% to 60% of patients who are resistant to first-generation EGFR tyrosine kinase inhibitors (TKIs).1 Osimertinib has definitive effects with manageable toxicities on patients with the EGFR T790M mutation who had been pretreated with previously approved EGFR TKIs. Nettet12. Yang JC-H, et al. J Clin Oncol 2024;35:1288–96 13. Wu SG, et al. Oncotarget 2016;7:12404–13 14. Mok TS, et al. N Engl J Med 2024;376:629–40 ... Data were previously presented: Hochmair, et al. OGP 2024, poster #P55. Corresponding author email address: [email protected] NettetMaximilian J. Hochmair,1 Alessandro Morabito,2 Desiree Hao,3 Cheng-Ta Yang,4 Ross A. Soo,5 ... S2137 (2024) 2. Ke, et al. J Thorac Oncol. 12(9), 1368-1375 (2024) 3. … the future symbol

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell …

Category:AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS …

Tags:Hochmair et al. j thorac oncol. 2017 12:s2137

Hochmair et al. j thorac oncol. 2017 12:s2137

Capmatinib in MET Exon 14–Mutated or MET-Amplified …

NettetJournal of Thoracic Oncology Abstracts from the 2024 Chicago Multidisciplinary Symposium in Thoracic Oncology - Chicago Multidisciplinary Symposium in Thoracic … NettetExperts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, …

Hochmair et al. j thorac oncol. 2017 12:s2137

Did you know?

Nettet1. mai 2024 · J Thorac Oncol, 12 (2024), pp. 1344-1356. View PDF View article View in Scopus Google Scholar. 26. ... F. Cappuzzo, R. Soo, M. Hochmair, et al. Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. NettetDiagnosis using hematoxylin and eosin staining alone showeds moderate agreement among pathologists in tumors with neuroendocrine morphology, but agreement …

Nettet5. des. 2024 · Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational … Nettet19. okt. 2024 · Hochmair M, Schwab S, Burghuber O et al. P2.03-025 prevalence of EGFR T790M mutation in NSCLC patients after afatinib ... J. Thorac. Oncol. 12(11), …

NettetA total of 3,086 advanced nonsmall cell lung cancer (NSCLC) patients from 11 studies have been identified. The aggregate efficacy parameters for treatment-naïve patients with EGFR-TKI-sensitizing mutations are as follows: ORR 79% (95% CI 75–84%), DCR 97% (95% CI 95–99%), 6-month PFS 83% (95% CI 80–87%), and 12-month PFS 64% (95% … Nettet25. nov. 2024 · This trial was conducted in compliance with the ethical principles originating from the Declaration of Helsinki, the International Council for Harmonisation guideline for Good Clinical Practice, and all applicable local regulations. All patients provided written informed consent before any screening procedures.

Nettet22. jun. 2024 · J Thorac Oncol 2015;10: 134-142. Crossref; Web of Science; Medline; Google Scholar. 9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus …

Nettet1. feb. 2024 · Tumor smaller than 2.0 cm was seen in 39.0% of patients, and limited resection was performed in 22.7%. The 30- and 90-day mortality rates were 0.43 and … the alcohol years filmNettet22. jun. 2024 · J Thorac Oncol 2015;10: 134-142. Crossref; Web of Science; Medline; Google Scholar. 9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell ... the alcott parkingNettetOutcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia the future synonymNettet12. jan. 2024 · Regarding the T790M status in plasma in patients treated with afatinib, Hochmair et al. reported that the T790M mutation was detected using a liquid biopsy in 47 out of 67 patients who had been treated with afatinib [ 16 ]. However, they did not use the cobas test, but rather the ddPCR system, which is a more sensitive assay than the … the alcott denver reviewsNettetMechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients. Checkpoint … the future televisionNettetIntroduction: The optimal role for postoperative radiotherapy (PORT) for thymoma and thymic carcinoma remains controversial. We used the National Cancer Data Base to … the alcooliséNettetFifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off. Conclusions: Pembrolizumab plus pemetrexed … the alco micro